About tepotinib
MET receptor tyrosine kinase inhibitor
Used for
- Treats adults with advanced non-small cell lung cancer caused by MET exon 14 skipping alterations.
Usual adult dose
450 mg by mouth once daily with food.
Common side effects
- Swelling, especially in the legs or feet
- Nausea, diarrhea, or vomiting
- Fatigue
- Liver enzyme increases
Important warnings
- Can cause serious or fatal lung inflammation; monitor for new breathing problems.
- Can cause liver injury; liver tests are monitored during treatment.
- May cause swelling and affect vision; report significant changes.
- Avoid grapefruit and grapefruit juice; they may increase drug levels.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase tepotinib exposure.
- Strong or moderate CYP3A inducers can lower tepotinib exposure.
- Tepotinib can increase levels of P-glycoprotein or BCRP substrate medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.